BACKGROUND: We have previously demonstrated that CD133 and CD39 are expressed by hematopoietic stem cells (HSC), which are mobilized after liver injury and target sites of injury, limit vascular inflammation, and boost hepatic regeneration. Plasma microparticles (MP) expressing CD39 can block endothelial activation. Here, we tested whether CD133 MP might be shed in a CD39-dependent manner in a model of liver injury and could potentially serve as biomarkers of liver failure in the clinic. METHODS: Wild-type and Cd39-null mice were subjected to acetaminophen-induced liver injury. Mice were sacrificed and plasma MP were isolated by ultracentrifugation. HSC and CD133 MP levels were analyzed by fluorescence-activated cell sorting. Patients were enrolled with acute (n=5) and acute on chronic (n=5) liver injury with matched controls (n=7). Blood was collected at admission and plasma CD133 and CD39 MP subsets were analyzed by fluorescence-activated cell sorting. RESULTS: HSC and CD133 MP levels were significantly increased only in the plasma of wild-type mice with acetaminophen hepatotoxicity (P<0.05). No increases in CD133 MP were noted in Cd39-null mice. Plasma MP increases were observed in patients with liver injury. These MP were characterized by significantly higher levels of CD39 (P<0.05). CONCLUSIONS: HSC and plasma CD133 MP levels increase in a CD39-dependent manner during experimental acute liver injury. Increased levels of CD39 MP are differentially noted in patients with liver injury. Further research is needed to determine whether MP fluxes are secondary to pathophysiologic insults to the liver or might reflect compensatory responses.
BACKGROUND: We have previously demonstrated that CD133 and CD39 are expressed by hematopoietic stem cells (HSC), which are mobilized after liver injury and target sites of injury, limit vascular inflammation, and boost hepatic regeneration. Plasma microparticles (MP) expressing CD39 can block endothelial activation. Here, we tested whether CD133 MP might be shed in a CD39-dependent manner in a model of liver injury and could potentially serve as biomarkers of liver failure in the clinic. METHODS: Wild-type and Cd39-null mice were subjected to acetaminophen-induced liver injury. Mice were sacrificed and plasma MP were isolated by ultracentrifugation. HSC and CD133 MP levels were analyzed by fluorescence-activated cell sorting. Patients were enrolled with acute (n=5) and acute on chronic (n=5) liver injury with matched controls (n=7). Blood was collected at admission and plasma CD133 and CD39 MP subsets were analyzed by fluorescence-activated cell sorting. RESULTS: HSC and CD133 MP levels were significantly increased only in the plasma of wild-type mice with acetaminophenhepatotoxicity (P<0.05). No increases in CD133 MP were noted in Cd39-null mice. Plasma MP increases were observed in patients with liver injury. These MP were characterized by significantly higher levels of CD39 (P<0.05). CONCLUSIONS: HSC and plasma CD133 MP levels increase in a CD39-dependent manner during experimental acute liver injury. Increased levels of CD39 MP are differentially noted in patients with liver injury. Further research is needed to determine whether MP fluxes are secondary to pathophysiologic insults to the liver or might reflect compensatory responses.
Authors: Rafaz Hoque; Muhammed Adnan Sohail; Steven Salhanick; Ahsan F Malik; Ayaz Ghani; Simon C Robson; Wajahat Z Mehal Journal: Am J Physiol Gastrointest Liver Physiol Date: 2012-03-01 Impact factor: 4.052
Authors: Jan Schulte Am Esch; Simon C Robson; Moritz Schmelzle; Constanze Duhme; Wolfgang Junger; Steven D Salhanick; Yu Chen; Yan Wu; Vasilis Toxavidis; Eva Csizmadia; Lihui Han; Shu Bian; Günter Fürst; Martina Nowak; Seth J Karp; Wolfram T Knoefel Journal: Ann Surg Date: 2013-04 Impact factor: 12.969
Authors: Z Gordon Jiang; Yan Wu; Eva Csizmadia; Linda Feldbrügge; Keiichi Enjyoji; John Tigges; Vasilis Toxavidis; Holger Stephan; Christa E Müller; Christina E Müller; C James McKnight; Alan Moss; Simon C Robson Journal: Purinergic Signal Date: 2014-08-28 Impact factor: 3.765
Authors: Stephanie Kuhn; Katrin Splith; Cindy Ballschuh; Linda Feldbrügge; Felix Krenzien; Georgi Atanasov; Christian Benzing; Hans-Michael Hau; Cornelius Engelmann; Thomas Berg; Jan Schulte Am Esch; Johann Pratschke; Simon C Robson; Moritz Schmelzle Journal: Purinergic Signal Date: 2018-09-22 Impact factor: 3.765
Authors: Cornelius Engelmann; Katrin Splith; Sandra Krohn; Adam Herber; Albrecht Boehlig; Stephan Boehm; Johann Pratschke; Thomas Berg; Moritz Schmelzle Journal: J Transl Med Date: 2017-09-06 Impact factor: 5.531
Authors: Jesus M Banales; Ariel E Feldstein; Hanna Sänger; Veronika Lukacs-Kornek; Gyongyi Szabo; Miroslaw Kornek Journal: Hepatol Commun Date: 2019-01-02
Authors: Linda Feldbrügge; Katrin Splith; Ines Kämmerer; Sandra Richter; Anna Riddermann; Santiago Andres Ortiz Galindo; Felix Krenzien; Tobias Müller; Eva Csizmadia; Johann Pratschke; Simon C Robson; Moritz Schmelzle Journal: Int J Mol Sci Date: 2020-08-20 Impact factor: 5.923
Authors: Felix Royo; Karin Schlangen; Laura Palomo; Esperanza Gonzalez; Javier Conde-Vancells; Agustin Berisa; Ana M Aransay; Juan M Falcon-Perez Journal: PLoS One Date: 2013-07-11 Impact factor: 3.240